Abstract
The high proportion of transmission events derived from asymptomatic or presymptomatic infections make SARS-CoV-2, the causative agent in COVID-19, difficult to control through the traditional non-pharmaceutical interventions (NPIs) of symptom-based isolation and contact tracing. As a consequence, many US universities have developed asymptomatic surveillance testing labs, to augment existing NPIs and control outbreaks on campus. We built a stochastic branching process model of COVID-19 dynamics to advise optimal control strategies in a university environment. Our model combines behavioral interventions in the form of group size limits to deter superspreading, symptom-based isolation, and contact tracing, with asymptomatic surveillance testing. We find that behavioral interventions offer a cost-effective means of epidemic control: group size limits of six or fewer greatly reduce superspreading, and rapid isolation of symptomatic infections can halt rising epidemics, depending on the frequency of asymptomatic transmission in the population. Surveillance testing can overcome uncertainty surrounding asymptomatic infections, with the most effective approaches prioritizing frequent testing with rapid turnaround time to isolation over test sensitivity. Importantly, contact tracing amplifies population-level impacts of all infection isolations, making even delayed interventions effective. Combination of behavior-based NPIs and asymptomatic surveillance also reduces variation in daily case counts to produce more predictable epidemics. Furthermore, targeted, intensive testing of a minority of high transmission risk individuals can effectively control the COVID-19 epidemic for the surrounding population. We offer this blueprint and easy-to-implement modeling tool to other academic or professional communities navigating optimal return-to-work strategies for the 2021 year.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CEB was funded by the Miller Institute for Basic Research at the University of California, Berkeley, the Branco Weiss Society in Science Fellowship from ETH Zurich, a DARPA PREEMPT Cooperative Grant (no. D18AC00031), and a COVID-19 Rapid Response Research grant from the Innovative Genomics Institute at the University of California, Berkeley. MB was supported by NIH grant no. R01-GM122061-03 and NSF EEID grant no. 2011109.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval was necessary for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Within-host model updated to reflect recent publication specific to SARS-CoV-2 viral dynamics (Ke et al. 2020). Structure of superspreading events updated to reflect both heterogeneity in individual infectiousness and in contact rates.
Data Availability
All code and corresponding data are made available in the article itself and in the cited open-access Github repository.
